



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018

Publication ID:

GMD1118069

Publication Date:

November 20, 2018

Pages:

68

Publisher:

Global Markets Direct

Region:

Global [1]

\$3,500.00

Publication License Type *

Single User License (PDF), \$3,500.00

Site License (PDF), \$7,000.00

Global License (PDF), \$10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Wilms Tumor Protein - Pipeline Review, H2 2018'; Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO.

The report 'Wilms Tumor Protein - Pipeline Review, H2 2018' outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Leukemias, Pancreatic Cancer, Soft Tissue Sarcoma, Solid Tumor, Adrenal Gland Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)

- The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Wilms Tumor Protein (WT33 or WT1) - Overview

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Scancell Holdings Plc

SELLAS Life Sciences Group Inc

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Wilms Tumor Protein (WT33 or WT1) - Drug Profiles

galinpepimut-S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCV-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ombipepimut-s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and

Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXM-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wilms Tumor Protein (WT33 or WT1) - Dormant Products

Wilms Tumor Protein (WT33 or WT1) - Discontinued Products

Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones

Featured News & Press Releases

Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

Aug 20, 2018: Inovio doses first patient in Phase I/IIa of INO-5401 and atezolizumab

Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

Jun 04, 2018: SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018

Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018

May 17, 2018: SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018

May 09, 2018: SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)

Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S)

Mar 19, 2018: SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

Feb 27, 2018: Data From SELLAS Life Sciences' Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology's Journal, Blood Advances

Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting

Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model

Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron's PD-1 Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Pipeline by Otsuka Holdings Co Ltd, H2 2018
Pipeline by Scancell Holdings Plc, H2 2018
Pipeline by SELLAS Life Sciences Group Inc, H2 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Pipeline by Vaximm AG, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Companies Mentioned:

Inovio Pharmaceuticals Inc
Otsuka Holdings Co Ltd
Scancell Holdings Plc
SELLAS Life Sciences Group Inc
Sumitomo Dainippon Pharma Co Ltd
Vaximm AG

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



Drug Pipeline

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/global-markets-direct/wilms-tumor-protein-wt33-or-wt1-pipeline-review-h2-2018>

Links

[1] <https://www.drugpipeline.net/region/global>